Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

June 30, 2011 compared to € 8.1 million in the same period of 2010. At the same time, general and administrative costs amounted to € 1.8 million in the period ended June 30, 2011 compared to € 1.8 million in the same period of 2010.

Net interest income/(cost) amounted to € 0.0 million for the period ended June 30, 2011, consistent with the € (0.0) million in the same period in 2010.

Cash and cash equivalents amounted to € 9.1 million at June 30, 2010, a decrease of € 8.8 million compared to € 17.9 million at December 31, 2010.  The decrease in cash and cash equivalents mainly stems from the operational cash outflow which amounted to € 8.8 million for the period ended June 30, 2011 (compared to an operating cash outflow of € 8.9 million for the period ended June 30, 2010).

Outlook

The Company's expenditure is expected to reduce in the second half of 2011 as the Company takes steps to extend its cash position into 2012. As AMT has not yet reached the point of generating significant revenues that could fund operations, we continue to explore additional opportunities for funding, including non-dilutive sources, such as grants, and collaborations with partners; AMT also tracks opportunities for raising additional capital in conjunction with its bankers.

Conference call and webcast presentation

AMT will conduct a conference call open to the public today at 3.30 p.m. CET, which will also be webcast. Netherlands dial in: +31 (0)20 707 5503; US dial in: +1 718 247 0884; UK dial in: +44 (0)20 7136 6285. Confirmation Code: 5149966

To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software.

The archived w
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to a ... Market” the global orthobiologics market was valued at USD 3,754.6 ... worth USD 5,519.9million in 2019at a CAGR of 5.9% from ... 50 years and above is afflicted by bone and joint ... the year 2020. This has and will continue to increase ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... Amarin Corporation plc,(NASDAQ: AMRN ) ("Amarin" or ... of Amarin, will present at the Acumen,BioFin Rodman & ... 12 noon Eastern time. The conference will be held ... New York. The presentation will be simultaneously webcast ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... that it is scheduled to present,on Monday, November ... Annual,Healthcare Conference and on Tuesday, November 6, 2007 ... Healthcare Conference. Anthony DiTonno,President and Chief Executive Officer, ...
... October 31 Revotar,Biopharmaceuticals AG., today announced first ... IIa pilot study in 14 patients with,stable COPD ... mg of Bimosiamose,twice a day. The study was ... Prof. Witt and the Respiratory Institute Wiesbaden, Dr.,Beeh. ...
Cached Biology Technology:Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 3NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD 2
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
(Date:8/29/2014)... been known about what genetic changes transform wild animals ... of whom is a University of Montana assistant professor, ... the development of the brain and the nervous system ... published Aug. 28 in Science and gives ... http://www.sciencemag.org/ ., The domestication of animals and plants, ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... too short, then you,re not alone. A team of scientists from Texas ... long life and they made important discoveries that bring longer life spans ... of The FASEB Journal ( http://www.fasebj.org ), describes how scientists ... the process discovered a new metabolic state correlating with long life. ...
... of two studies published in the current issue of ... cerebral ischemia and ischemic stroke in rats may significantly ... found that administering bone marrow stromal stem cells (MSC) ... which coincided with activation of microglia and new blood ...
... This release is available in German . , ... reliable testing of HIV inhibitors. This system was developed under ... Virology. At the heart of the system are cultured human ... that signal HIV infection by producing a red fluorescent protein. ...
Cached Biology News:Longevity breakthrough: The metabolic state of mitochondria controls life span 2Stroke research takes 2 steps forward 2Stroke research takes 2 steps forward 3A powerful new technology to identify HIV inhibitors 2
Request Info...
...
...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
Biology Products: